Sunday, September 17, 2000
14:00-17:00

Chairman's Introduction

Development and manufacture of the world's first tissue-engineered human skin equivalent
Nancy Parenteau, USA

Apligraf®: Phenotypic characteristics associated with wound healing
Peter Schmid, Switzerland

Apligraf® sets new bacterial and viral safety standards for tissue-engineering
David Onions, UK

Discussion

Apligraf® vs standard of care in healing neuropathic diabetic foot ulcers: Results of 208-patient trial
Aristidis Veves, USA

Apligraf®: A new approach to risk factor management in patients with diabetic foot ulcers
Mike Sabolinski, USA

Apligraf® healing process: From application to wound closure
Vincent Falanga, USA

Health economic impact of Apligraf® in healing diabetic foot ulcers
Ken Redekop, The Netherlands

Discussion

Chairman's Close

ICC - Jerusalem International Convention Center - Hall D

Andrew Boulton, UK
Vincent Falanga, USA

Novartis Pharma

FOR ENQUIRIES PLEASE CONTACT
Bonnie Molloy
ICC EUROPE
36 East Field Close,
Headington, Oxford OX3 7SH, UK
Tel: + 44 1865 39 55 86
Fax: + 44 1865 39 55 75
E-mail: bmolloy@icclink.com